carmustine medac (previously carmustine obvius)
medac gesellschaft für klinische spezialpräparate mbh - carmustine - hodgkin disease; lymphoma, non-hodgkin - antineoplastické činidlá - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).
lenalidomid stada 25 mg tvrdé kapsuly
stada arzneimittel ag, nemecko - lenalidomid - 59 - immunopraeparata
lenalidomid stada 15 mg tvrdé kapsuly
stada arzneimittel ag, nemecko - lenalidomid - 59 - immunopraeparata
lenalidomid stada 10 mg tvrdé kapsuly
stada arzneimittel ag, nemecko - lenalidomid - 59 - immunopraeparata
lenalidomid stada 5 mg tvrdé kapsuly
stada arzneimittel ag, nemecko - lenalidomid - 59 - immunopraeparata
lenalidomid pharmevid 25 mg
pharmevid s.r.o., slovensko - lenalidomid - 59 - immunopraeparata
lenalidomid pharmevid 15 mg
pharmevid s.r.o., slovensko - lenalidomid - 59 - immunopraeparata
lenalidomid pharmevid 10 mg
pharmevid s.r.o., slovensko - lenalidomid - 59 - immunopraeparata
lenalidomid pharmevid 5 mg
pharmevid s.r.o., slovensko - lenalidomid - 59 - immunopraeparata
lenalidomid sandoz 25 mg
sandoz pharmaceuticals d.d., slovinsko - lenalidomid - 59 - immunopraeparata